what is a microdose of glp-1 Microdosing GLP-1's / Wellness Services / Services Microdosing GLP-1 Medications | Achieve

Description

Weight loss goals are now disease-driven, not cosmetic 5% minimum meaningful benefit 10% required for most metabolic conditions 15% often needed for OSA, HFpEF, MASH, and severe obesity Medication choice is guided by comorbidities GLP-1 receptor agonists and dual GIP/GLP-1 agents are prioritized in patients with: Prediabetes & type 2 diabetes ASCVD Heart failure with preserved EF Metabolic liver disease Obstructive sleep apnea Cardiovascular outcomes now matter Semaglutide 2.4 mg demonstrated a significant reduction in major cardiovascular events even in people without diabetes

In the past year, the growth of prescription drug utilization and spending has much to do with the use of GLP-1 agonists to treat diabetes and obesity, along with immunology therapy, and lipid meds, along with specialty medicines now accounting for over half of spending up from 49% in 2018

Adverse reactions were compared between combination therapy and monotherapy (GLP-1 RAs or metformin alone), followed by stratified analyses by gender, age, and body weight

While the absolute risk increase was modest, our findings point to an important potential adverse effect that clinicians should consider, especially in patients with predisposing factors for GERD

President Donald Trump signed an executive Saturday that aims to accelerate research and approval of psychedelic-based therapies for conditions such as PTSD.